
News|Articles|February 1, 2010
Formulary Digital Edition February 2010
Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis; Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes; and Agents in late-stage development for renal diseases
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement























